Aspire-Lakewood Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $8.73M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Aspire-Lakewood has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Aspire-Lakewood filed with the SEC
Holdings Board Approves $10 Million Share Repurchase Program
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
BIOPHARMA HOLDINGS, INC. ANNOUNCES CORPORATE NAME CHANGE TO ASPIRE-LAKEWOOD HOLDINGS, INC.
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Aspire Biopharma Completes Acquisition of Dura
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems , a Leading Global Automotive
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter
Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in
Regulation FD disclosure · EX-99.1 to Form 8-K
BIOPHARMA ANNOUNCES $21 MILLION PRIVATE PLACEMENT BY SELECT INVESTORS, STRENGTHENING BALANCE SHEET, CAPITAL POSITION, AND FORTIFYING
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharma Holdings, Inc., Announces Michael C. Howe – with Decades of Experience at Leading and Building Brands in the Healthcare
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Aspire Biopharma Holdings, Inc. Announces the Execution
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company
Other events · EX-99.1 to Form 8-K
Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders
Material agreement · Other events · EX-99.1 to Form 8-K
Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders
Other events · EX-99.1 to Form 8-K
Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing April 11, 2022
Other events · EX-99.1 to Form 8-K
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
Other events · EX-99.1 to Form 8-K
PowerUp Acquisition Corp. Announces Pricing of $250 Million Initial
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
PowerUp Acquisition Corp. Announces Closing of $287,500,000 Initial
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K